Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP430304.RAiKolGChZ932Jhn07pEcK29j40Hoc9vRDRvuIUBprEqg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP430304.RAiKolGChZ932Jhn07pEcK29j40Hoc9vRDRvuIUBprEqg130_assertion type Assertion NP430304.RAiKolGChZ932Jhn07pEcK29j40Hoc9vRDRvuIUBprEqg130_head.
- NP430304.RAiKolGChZ932Jhn07pEcK29j40Hoc9vRDRvuIUBprEqg130_assertion description "[We also describe the recent development and validation of the most studied mucins (MUC1 and MUC16), ErbB-2 (Her2/neu) and folate binding protein as target-based immunotherapy of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP430304.RAiKolGChZ932Jhn07pEcK29j40Hoc9vRDRvuIUBprEqg130_provenance.
- NP430304.RAiKolGChZ932Jhn07pEcK29j40Hoc9vRDRvuIUBprEqg130_assertion evidence source_evidence_literature NP430304.RAiKolGChZ932Jhn07pEcK29j40Hoc9vRDRvuIUBprEqg130_provenance.
- NP430304.RAiKolGChZ932Jhn07pEcK29j40Hoc9vRDRvuIUBprEqg130_assertion SIO_000772 14755889 NP430304.RAiKolGChZ932Jhn07pEcK29j40Hoc9vRDRvuIUBprEqg130_provenance.
- NP430304.RAiKolGChZ932Jhn07pEcK29j40Hoc9vRDRvuIUBprEqg130_assertion wasDerivedFrom befree-2016 NP430304.RAiKolGChZ932Jhn07pEcK29j40Hoc9vRDRvuIUBprEqg130_provenance.
- NP430304.RAiKolGChZ932Jhn07pEcK29j40Hoc9vRDRvuIUBprEqg130_assertion wasGeneratedBy ECO_0000203 NP430304.RAiKolGChZ932Jhn07pEcK29j40Hoc9vRDRvuIUBprEqg130_provenance.